InMed Pharmaceuticals Inc. (INM)
$0.62
$-0.03
(-4.46%)
As on 11-May-2026 16:00EDT
Market cap
$2 Mln
Revenue (TTM)
$664 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-47.2
-
Face value
--
-
Shares outstanding
3,314,063
10 Years Aggregate
CFO
$-55.17 Mln
EBITDA
$-65.91 Mln
Net Profit
$-77.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
InMed Pharmaceuticals (INM)
| -41.4 | -13.3 | -37.9 | -73.5 | -70.8 | -79.1 | -53.1 |
|
BSE Sensex*
| -11.9 | -3.9 | -11.5 | -6.2 | 6.4 | 8.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
InMed Pharmaceuticals (INM)
| -77.6 | -79.4 | -93.8 | -60.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
InMed Pharmaceuticals (INM)
|
0.6 | 2.2 | 663.9 | -181.5 | -27.4 | -5.3 | -- | 0.2 |
| 15.7 | 1,958.6 | 298.3 | 298.2 | 32.7 | 63.9 | 7.1 | 3.5 | |
| 6.5 | 340.5 | 0.0 | -35.1 | 131,201.1 | -71 | -- | 7.2 | |
| 55.8 | 5,455.8 | 0.0 | -383.2 | -- | -40.4 | -- | 4.1 |
Shareholding Pattern
View DetailsAbout InMed Pharmaceuticals (INM)
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed... Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Address: 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 Read more
-
President, CEO & Director
Mr. Eric A. Adams B.S. Chem., M.I.B.
-
President, CEO & Director
Mr. Eric A. Adams B.S. Chem., M.I.B.
-
Headquarters
Vancouver, BC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for InMed Pharmaceuticals (INM)
What is the current share price of InMed Pharmaceuticals Inc (INM) Today?
The share price of InMed Pharmaceuticals Inc (INM) is $0.62 (NASDAQ) as of 11-May-2026 16:00 EDT. InMed Pharmaceuticals Inc (INM) has given a return of -70.82% in the last 3 years.
What is the current PB & PE ratio of InMed Pharmaceuticals Inc (INM)?
Since, TTM earnings of InMed Pharmaceuticals Inc (INM) is negative, P/E ratio is not available.
The P/B ratio of InMed Pharmaceuticals Inc (INM) is 0.24 times as on 11-May-2026, a 96 discount to its peers’ median range of 6.58 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.40
|
0.18
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of InMed Pharmaceuticals Inc (INM)?
The 52-week high and low of InMed Pharmaceuticals Inc (INM) are Rs 7.98 and Rs 0.58 as of 12-May-2026.
What is the market cap of InMed Pharmaceuticals Inc (INM)?
InMed Pharmaceuticals Inc (INM) has a market capitalisation of $ 2 Mln as on 11-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in InMed Pharmaceuticals Inc (INM)?
Before investing in InMed Pharmaceuticals Inc (INM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.